Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofetuzumab pelidotin in advanced solid tumors
NCT02222922Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2014
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cofetuzumab pelidotin in solid tumor, ovarian cancer, non-small cell lung cancer (NSCLC) and 1 more (4 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Number of Participants With Treatment-Emergent Adverse Events up to 32 months and 1 more. Started Oct 2014; status: completed.
02
Drugs
cofetuzumab pelidotin
03
Conditions
solid tumorovarian cancernon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02222922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222922.